DFDavid C. Fajgenbaum

David C. Fajgenbaum

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


David C. Fajgenbaum has a total of 768 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Idiopathic Multicentric Castleman Disease Unresponsive to One IL-6 Inhibitor May Respond to Another IL-6 Inhibitor

    by Kayla McHugh, Yuan Huang, Bridget Austin, Larissa Borys, Abiola H. Irvine, Daisy V Alapat, Adam Bagg, Amy Chadburn, Mary Jo Lechowicz, Megan S Lim, et al.

    Idiopathic multicentric Castleman disease (iMCD) is a rare hematologic disorder defined by lymphadenopathy with distinctive histopathology and systemic inflammation that can progress to multiorgan failure. Siltuximab, a monoclonal antibody targeting the interleukin-6 (IL-6) cytokine, is the only FDA-approved treatment for iMCD and is considered first-line therapy. Tocilizumab, an IL-6 receptor antagonist, approved for iMCD in Japan and used off-label is often viewed as clinically interchangeable with siltuximab due to shared pathway inhibition. Limited treatment alternatives exist for patients whose disease is refractory to IL-6 inhibition. Using two independent iMCD patient registries, we identified patients who received siltuximab and tocilizumab at different periods and had an assessable response to each inhibitor. Eight out of 14 patients who received both therapies were refractory to the first and then responsive to the second IL-6 inhibitor; six patients were refractory to both IL-6 inhibitors. Responses were durable over available follow-up and were accompanied by significant improvements in inflammatory markers and disease severity scores. While a subset of patients may have had improved response to the second IL-6 inhibitor due to shorter treatment durations or the use of other medications, all were refractory after receiving at least three doses of the first IL-6 inhibitor. These findings suggest that there may be different IL-6-related mechanisms across patients and that selected patients who do not respond to an initial IL-6 inhibitor should be considered for a second IL-6 inhibitor.

  • Open Access

    Vascular smooth muscle cell abundance is a hallmark of Castleman Disease

    by Joshua D. Brandstadter, Samuel Meili, Joseph Zinski, Hung-Wei Cheng, Dorottya Laczko, Michael V. Gonzalez, Subin S. George, Megan S Lim, Adam Bagg, Yves Stanossek, et al.

    Castleman disease (CD) is an inflammatory disorder characterized by lymphadenopathy with distinctive histologic features, yet its pathophysiology remains poorly understood. This delays diagnoses and limits treatments, leading to additional morbidity and mortality. We used single- cell and spatial transcriptomics to characterize lymph nodes from unicentric CD (UCD) compared with non-specific inflammatory lymphadenopathies. While hematopoietic cells showed few compositional or transcriptional differences, lymph node stromal cells exhibited marked alterations in UCD, most notably an increased abundance of vascular smooth muscle cells (VSMCs) and broadly increased stromal signaling activity. A generalized linear model distinguished histologically indeterminate lymph nodes resembling UCD from non-specific inflammation most accurately using stromal rather than hematopoietic cell composition. Immunohistochemical staining for the VSMC marker CD146 (Melanoma Cell Adhesion Molecule, MCAM) further discriminated UCD from other causes of lymphadenopathy. Together, these findings identify increased VSMC abundance as a hallmark of UCD and suggest that this stromal signature can be leveraged to improve pathologic diagnosis and patient stratification.

  • Open Access

    Pediatric Idiopathic Multicentric Castleman Disease Is Often Severe But Responsive to Siltuximab

    by Bridget Austin, Sheila K. Pierson, Kelley C. Dacus, Mateo Sarmiento Bustamante, Saishravan Shyamsundar, Larissa Borys, Kayla McHugh, Abiola Irvine, Yoojin Jo, Adam Bagg, et al.

    Background: Idiopathic multicentric Castleman disease (iMCD) is a potentially fatal immunologic disorder marked by widespread lymphadenopathy and inflammation. Siltuximab, an interleukin‐6 (IL‐6) inhibitor, is the only FDA‐approved treatment for adult patients with iMCD. Limited data exist on pediatric iMCD or its responsiveness to siltuximab. We hypothesize that pediatric iMCD patients will present and respond similarly to adult patients. Procedure: We queried ACCELERATE, the largest global iMCD registry with expert‐confirmed diagnoses. We analyzed two iMCD cohorts: pediatric patients (18 years of age or younger at symptom onset) and adults. We assessed both disease severity, using a modified CHA (C‐reactive protein [CRP], hemoglobin, albumin) score, and response to treatment. A response was defined as normalization in greater than 50% of abnormal clinical parameters and was considered durable if no new regimens were started within 1 year of initiating the index regimen. Results: Pediatric iMCD patients ( N = 30) had higher CHA scores at diagnosis (1.67 vs. 1.31, p = 0.024) than adult iMCD cases ( N = 96), indicating greater disease severity and higher CRP. Pediatric and adult iMCD patients had similar responses to siltuximab ± CS (12/14, 86% vs. 35/48, 73%, p = 0.48) as well as other treatments. Conclusions: In the largest pediatric iMCD analysis to date, we found more severe disease and similar responses to siltuximab in children compared to adults.

  • Open Access

    Clusterin expression and germinal center morphometry help distinguish idiopathic multicentric castleman disease from select lymphadenopathies

    by Michael V. Gonzalez, Kaiwen Wang, Joseph Zinski, Melanie D. Mumau, Katherine S. Forsyth, Abiola H. Irvine, Joshua Brandstadter, Stacy G. Guzman, Lu Zhang, Sheila K. Pierson, et al.

    Idiopathic multicentric Castleman disease (iMCD) is a heterogeneous cytokine storm disorder involving systemic inflammation, multicentric lymphadenopathy with characteristic histopathology, and life-threatening multiple organ dysfunction. Patients can present with symptoms ranging from thrombocytopenia, anasarca, fever/elevated C-reactive protein (CRP), reticulin myelofibrosis, renal dysfunction, and organomegaly (iMCD-TAFRO) to thrombocytosis, hypergammaglobulinemia, and plasmacytosis (iMCD-IPL), with patients not falling into either group (iMCD-NOS). The molecular mechanisms across the clinical subtypes have not been elucidated and new effective treatments are needed. Here, we performed bulk RNA sequencing and targeted gene expression quantification in lymph node tissue from multiple iMCD clinical subtypes, pathologically related disorders, and controls. We identified 249 upregulated and 42 downregulated genes in iMCD-TAFRO lymph node tissue, which were enriched in the following pathways: angiogenesis, cell proliferation, and various aspects of the humoral and innate immune response. The targeted gene expression analysis revealed shared differentially expressed genes (DEGs) across all three iMCD clinical subtypes, including SPP1 , XBP1 , PRDM1 , and CLU . We identified unique DEGs in each iMCD clinical subtype, including PLA2G2A, MSR1, IL8 (iMCD-TAFRO), IL9, KIR3DL1, IL18RAP (iMCD-IPL), and IL7, TLR8, and CX3CR1 (iMCD-NOS). Since Clusterin ( CLU ) was significantly upregulated in iMCD but not in related conditions, we performed immunohistochemistry and observed that Clusterin is elevated in the germinal center and mantle zone regions of iMCD patient lymph nodes. A composite model incorporating CLU expression in these lymph node compartments with germinal center features demonstrated strong performance in differentiating iMCD from selected lymphadenopathies. Together, this work identified pathways dysregulated in iMCD lymph nodes and suggests that Clusterin, particularly when integrated with germinal center features, could be a novel biomarker.

  • Open Access

    Development and Validation of the Idiopathic Multicentric Castleman Disease Symptom Burden Scale (ISBUS): Protocol for an International Multistage Mixed Methods Study

    by Philip A Powell, Anju Keetharuth, Sé Maria Frances, Jill Carlton, Kelly Makarounas-Kirchmann, Antonio Adolfo Guerra Soares Brandão, Karthik Ramasamy, Francis Shupo, Kelley C Dacus, Corey Casper, et al.

    Background: Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder that is associated with a broad range of symptoms, including constitutional, gastrointestinal, neuropsychiatric, dermatologic, respiratory, and hematologic or lymphoreticular problems. These broad symptoms can impact the daily lives of people living with iMCD, creating a high symptom burden. Despite this, no robust, disease-specific patient-reported outcome measure (PROM) for subjective iMCD symptom burden exists. This limits accurate symptom monitoring, impacts sensitive end point selection in clinical trials, and represents a regulatory gap in patient-centered evidence generation when evaluating iMCD treatments. Objective: This protocol describes the international multistakeholder Idiopathic Multicentric Castleman Disease Symptom Burden Scale (ISBUS) project. The primary aim of this project is to develop and preliminarily evaluate the measurement properties of a novel PROM for capturing symptom burden (ie, perceived symptom frequency and impact on daily life) in people living with iMCD. The central objective is to produce a valid and robust PROM that can be used to assess iMCD symptom burden in research, clinical trials, and symptom monitoring in clinical practice. Methods: The project has a mixed methods design, split into 4 sequential stages, with collaborative advisory input throughout. Stage 1 uses existing data and consultation with expert clinical and patient advisors to generate draft PROM content. Stage 2 uses qualitative cognitive debriefing interviews (n=10) to evaluate the content validity of the draft PROM content and enable meaningful revisions. Stage 3 involves a cross-sectional quantitative survey design in people living with iMCD (n≥50), allowing for psychometric analyses of structural validity (using classical test theory and/or Rasch methodology), construct validity (known-group validity and correlational methods), and internal consistency reliability (Cronbach α). Stage 4 uses a mixed methods design, including longitudinal quantitative survey evidence (n≥20) and qualitative interviews (n=10), triangulated to estimate preliminary meaningful change estimates for the new PROM. The project is international in scope, with primary data collection in 6 countries (ie, Australia, Brazil, Canada, New Zealand, the United Kingdom, and the United States). Results: Funding for ISBUS began in June 2023 and is ongoing. As of March 2026, stage 3 had been completed, with 51 people living with iMCD completing the survey, and stage 4 was ongoing, with 32 follow-up surveys completed. Analyses for stages 1-3 were completed and are expected to be published in 2026, followed by stage 4 findings in 2027. Conclusions: The aim of the ISBUS project is to produce a novel symptom burden PROM codeveloped with patients with iMCD to measure what matters to patients with iMCD. It is anticipated that the new PROM will be used in iMCD research, as a secondary end point in trials, and as a clinical tool to monitor symptom burden in the management of iMCD. Trial Registration: ClinicalTrials.gov NCT05995834; https://clinicaltrials.gov/study/NCT05995834 International Registered Report Identifier (IRRID): DERR1-10.2196/96022

  • Open Access

    Characterization of the genotypic and phenotypic spectrum of TCF7L2-related neurodevelopmental disorder (TRND)

    by Sally Nijim, Mimi Kim, Melissa Denish, Michael V. Gonzalez, Joseph Zinski, Claudine Rieubland, Dominique Braun, Elsebet Ostergaard, Amelle Shillington, Laurence Faivre, et al.


  • Open Access

    Identifying repurposing opportunities using computational pharmacophenomics in major depressive disorder: a meta-analysis and systematic review of glabellar injection of Botulinum Toxin A

    by Nicholas R. Fragola, Lee Lancashire, Jennifer K. Visser-Rogers, Elliott W. Sharp, Charlotte Blewitt, Matthew M. Goddeeris, David C. Fajgenbaum


  • Open Access

    Lenalidomide‐Dexamethasone as an Effective and Well‐Tolerated Treatment Option for Refractory Rosai‐Dorfman‐Destombes Disease: A Clinical and Pharmacophenomic Study

    by Emily Leung, Nicholas R. Fragola, Elliott W. Sharp, Rebecca A. Harrison, Erica Peterson, Julia Varghese, Shannon Jackson, Xiaotian (Julie) You, Elysha VanderVeer, Mark Trinder, et al.

    A combined clinical and computational pharmacophenomic study from the Coastal Rare Inflammatory Diseases Program and Every Cure.


  • Castleman Disease and Rosai-Dorfman-Destombes Disease

    by Joshua D. Brandstadter, Kathryn Lurain, Sunita D. Nasta, David C. Fajgenbaum

  • Open Access

    Development and Validation of the Idiopathic Multicentric Castleman Disease Symptom Burden Scale (ISBUS): Protocol for an International Multistage Mixed Methods Study (Preprint)

    by Philip A Powell, Anju Keetharuth, Sé Maria Frances, Jill Carlton, Kelly Makarounas-Kirchmann, Antonio Adolfo Guerra Soares Brandão, Karthik Ramasamy, Francis Shupo, Kelley C Dacus, Corey Casper, et al.

    BACKGROUND Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder that is associated with a broad range of symptoms, including constitutional, gastrointestinal, neuropsychiatric, dermatologic, respiratory, and hematologic or lymphoreticular problems. These broad symptoms can impact the daily lives of people living with iMCD, creating a high symptom burden. Despite this, no robust, disease-specific patient-reported outcome measure (PROM) for subjective iMCD symptom burden exists. This limits accurate symptom monitoring, impacts sensitive end point selection in clinical trials, and represents a regulatory gap in patient-centered evidence generation when evaluating iMCD treatments. OBJECTIVE This protocol describes the international multistakeholder Idiopathic Multicentric Castleman Disease Symptom Burden Scale (ISBUS) project. The primary aim of this project is to develop and preliminarily evaluate the measurement properties of a novel PROM for capturing symptom burden (ie, perceived symptom frequency and impact on daily life) in people living with iMCD. The central objective is to produce a valid and robust PROM that can be used to assess iMCD symptom burden in research, clinical trials, and symptom monitoring in clinical practice. METHODS The project has a mixed methods design, split into 4 sequential stages, with collaborative advisory input throughout. Stage 1 uses existing data and consultation with expert clinical and patient advisors to generate draft PROM content. Stage 2 uses qualitative cognitive debriefing interviews (n=10) to evaluate the content validity of the draft PROM content and enable meaningful revisions. Stage 3 involves a cross-sectional quantitative survey design in people living with iMCD (n≥50), allowing for psychometric analyses of structural validity (using classical test theory and/or Rasch methodology), construct validity (known-group validity and correlational methods), and internal consistency reliability (Cronbach α). Stage 4 uses a mixed methods design, including longitudinal quantitative survey evidence (n≥20) and qualitative interviews (n=10), triangulated to estimate preliminary meaningful change estimates for the new PROM. The project is international in scope, with primary data collection in 6 countries (ie, Australia, Brazil, Canada, New Zealand, the United Kingdom, and the United States). RESULTS Funding for ISBUS began in June 2023 and is ongoing. As of March 2026, stage 3 had been completed, with 51 people living with iMCD completing the survey, and stage 4 was ongoing, with 32 follow-up surveys completed. Analyses for stages 1-3 were completed and are expected to be published in 2026, followed by stage 4 findings in 2027. CONCLUSIONS The aim of the ISBUS project is to produce a novel symptom burden PROM codeveloped with patients with iMCD to measure what matters to patients with iMCD. It is anticipated that the new PROM will be used in iMCD research, as a secondary end point in trials, and as a clinical tool to monitor symptom burden in the management of iMCD. CLINICALTRIAL ClinicalTrials.gov NCT05995834; https://clinicaltrials.gov/study/NCT05995834 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/96022